GlassScriptPhysician profile
Sarah E Souverain
NPI 1942605027
$4,694.73
in general payments reported to CMS, 2019-2025
56 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.23 · 2022: $851 · 2023: $1,176 · 2024: $1,202 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $604.47 | 2022-2025 | |
| Celgene Corporation | $358.28 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Janssen Biotech, INC. | $347.76 | 2022-2025 | Rybrevant, Erleada, Balversa |
| Astrazeneca Pharmaceuticals LP | $347.34 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $302.77 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $177.74 | 2022-2025 | |
| Daiichi Sankyo INC. | $172.43 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $148.02 | 2022-2025 | Retevmo, Verzenio, Jaypirca |
| Genmab U.S., INC. | $105.65 | 2023-2025 | Epkinly |
| Pfizer INC. | $96.88 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.98 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $94.88 | 2023-2025 | |
| Incyte Corporation | $91.76 | 2022-2025 | Monjuvi, Zynyz, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $87.38 | 2022-2023 | Imbruvica |
| Astellas Pharma US INC | $87.33 | 2023-2025 | Xospata, Vyloy, Padcev |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Souverain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.